DocumentRX-7368
Issued
Read2 min

FDA Hands Cipla's InvaGen New York Plant 'No Action Indicated' Status

FDA classifies Cipla's InvaGen Pharmaceuticals plant in Hauppauge, Long Island as No Action Indicated on November 17, 2026, after an October 19-22 inspection found no violations.

TAG P-1559 · 465 words on the filing

Cipla’s US manufacturing facility gets ‘No Action Indicated’ status from FDA - TradingView
Cipla’s US manufacturing facility gets ‘No Action Indicated’ status from FDA - TradingViewjarmoluk / pixabay

Summary of findings

  • FDA issued the No Action Indicated classification on November 17, 2026.
  • The inspection of the Hauppauge, Long Island facility ran October 19-22, 2026.
  • NAI means no objectionable conditions or regulatory violations were found.
  • The facility belongs to InvaGen Pharmaceuticals Inc, Cipla's wholly-owned US subsidiary.
  • Cipla disclosed the outcome in a regulatory filing on Tuesday evening.

The US Food and Drug Administration has classified Cipla's InvaGen Pharmaceuticals manufacturing site in Hauppauge, Long Island, New York, as No Action Indicated (NAI) — the cleanest outcome a facility inspection can produce. The agency issued the classification on November 17, 2026, roughly a month after inspectors closed their work at the plant.

Cipla Ltd disclosed the result in a regulatory filing late on Tuesday. The facility, operated by InvaGen Pharmaceuticals Inc, Cipla's wholly-owned US subsidiary, underwent the FDA inspection from October 19 to October 22, 2026 — a four-day, on-site engagement covering the Hauppauge plant's manufacturing operations.

What Does NAI Actually Mean?

For those who track inspection outcomes across a portfolio, the classification ladder is familiar. NAI means the FDA found no objectionable conditions or regulatory violations during the inspection. In practical terms, the site exits the cycle without a Form 483 list of observations, without warning-letter exposure, and without any follow-up remediation obligations tied to this visit.

It is the outcome quality and regulatory-affairs teams file away as a clean bill: no CAPA plans to open, no management responses to draft, no re-inspection window to plan around from this event.

What Does This Change for Cipla?

The practical question is what a clean inspection changes for the company's US business. An NAI classification removes the single most common source of approval friction for a generic-drug maker — facility-based regulatory findings that stall ANDA reviews and force reassessment of committed corrective actions. With the Hauppauge site in good standing, pending and future submissions that list the facility carry one less point of attack in the FDA's review.

Cipla has been building its US business in part through InvaGen, acquired in 2016, and the Long Island site is a core piece of that American manufacturing footprint. Sustained compliance at the plant matters for the pipeline of products that depend on it as a listed manufacturing site.

The Mechanics of the Outcome

The sequence, per the company's filing:

  • October 19–22, 2026: FDA inspectors conduct the on-site inspection of InvaGen Pharmaceuticals Inc's facility in Hauppauge, Long Island, New York.
  • Inspection window closes with no objectionable conditions or regulatory violations identified.
  • November 17, 2026: The FDA formally issues the NAI classification to the company.
  • Tuesday evening: Cipla discloses the classification through a regulatory filing.

The roughly four-week gap between the end of the physical inspection and the classification date reflects the agency's standard post-inspection administrative process, during which the district office finalizes its classification decision.

A Clean Classification, Filed and Banked

For a plant that anchors a US generics portfolio, an NAI letter is quiet, unglamorous and exactly what operations leadership wants to see — no findings, no letters, no remediation.

via FDA industry wire (Google News) (Source)

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.

13 articles

Linked filings

  1. E-9124
  2. E-4696
  3. P-6323
  4. K-6477
  5. E-6700

« Previous filingNext filing »